On March 19, 2025, Benitec Biopharma Inc. reported positive interim results from its BB-301 clinical study for Oculopharyngeal Muscular Dystrophy, showing significant improvements in swallowing function and reductions in dysphagic symptoms for three subjects treated, with no severe adverse events observed.